, Columnist
Biotech's IPO Market Looks Just Right -- For Now
It's bounced back from the doldrums but isn't totally frothy yet.
This article is for subscribers only.
Biotech stocks are starting to hit some benchmarks of bubbliness. Rapidly rising prices? Check. Greater tolerance of drug-trial failure? Check.
An out-of-control IPO market? We're not quite there yet. The IPO window is far more active than last year, but still seems in no immediate danger of overheating.